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The increase of proinflammatory cytokines in vaginal
secretions may serve as a surrogate marker of unwanted
inflammatory reaction to microbicide products topically
applied for the prevention of sexually transmitted dis-
eases, including HIV-1. Interleukin (IL)-1 and IL-6 have
been proposed as indicators of inflammation and in-
creased risk of HIV-1 transmission; however, the lack of
information regarding detection platforms optimal for
vaginal fluids and interlaboratory variation limit their use
for microbicide evaluation and other clinical applications.
This study examines fluid matrix variants relevant to
vaginal sampling techniques and proposes a model for
interlaboratory comparisons across current cytokine de-
tection technologies. IL-1 and IL-6 standards were
measured by 12 laboratories in four countries, using 14
immunoassays and four detection platforms based on
absorbance, chemiluminescence, electrochemilumines-
cence, and fluorescence. International reference prepara-
tions of cytokines with defined biological activity were
spiked into (1) a defined medium simulating the compo-
sition of human vaginal fluid at pH 4.5 and 7.2, (2)
physiologic salt solutions (phosphate-buffered saline and
saline) commonly used for vaginal lavage sampling in
clinical studies of cytokines, and (3) human blood serum.
Assays were assessed for reproducibility, linearity, ac-
curacy, and significantly detectable fold difference in
cytokine level. Factors with significant impact on cytokine
recovery were determined by Kruskal-Wallis analysis of
variance with Dunn’s multiple comparison test and mul-
tiple regression models. All assays showed acceptable
intra-assay reproducibility; however, most were associated
with significant interlaboratory variation. The smallest
reliably detectable cytokine differences (P< 0.05) derived
from pooled interlaboratory data varied from 1.5- to 26-
fold depending on assay, cytokine, and matrix type. IL-6
but not IL-1 determinations were lower in both saline
and phosphate-buffered saline as compared to vaginal
fluid matrix, with no significant effect of pH. The (elec-
tro)chemiluminescence-based assays were most discrimi-
native and consistently detected<2-fold differences within
each matrix type. The Luminex-based assays were less
discriminative with lower reproducibility between labo-
ratories. These results suggest the need for uniform
vaginal sampling techniques and a better understanding
of immunoassay platform differences and cross-validation
before the biological significance of cytokine variations can
be validated in clinical trials. This investigation provides
the first standardized analytic approach for assessing
differences in mucosal cytokine levels and may improve
strategies for monitoring immune responses at the vaginal
mucosal interface.
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Topical microbicides are considered a leading preventive
strategy to reduce the sexual transmission of HIV-1 worldwide.
To be effective, topical microbicides should have minimal or no
impact on the natural structural and functional integrity of the
human cervicovaginal mucosa.1–3 Cytokines such as interleukin
(IL)-1 and IL-6 have emerged as sensitive indicators of compound-
induced mucosal toxicity and are elevated with bacterial vaginosis
and sexually transmitted infections (STI), conditions associated
with inflammation known to increase the risk of acquiring or
transmitting HIV-1 infection.4–7 IL-1 and IL-6 can up-regulate
HIV-1 replication,8 and concentrations in vaginal secretions cor-
relate with proviral HIV-1 DNA and cell-associated/cell-free HIV-1
RNA levels.9–12 Therefore, cytokines have been proposed to be
part of screening algorithms for microbicide safety evaluation, and
to this purpose, an increasing number of clinical studies have
collected cervicovaginal secretions, usually sampled by lavage with
normal saline or phosphate-buffered saline (PBS).4–6,12–15 How-
ever, the detection of cytokines in the complex biological
background (matrix) of these fluids may be affected by multiple
biological factors (e.g., abundance of high molecular weight
proteins such as the mucins and pH variations that depend on
microflora, menstrual cycle, and sexual intercourse) as well as
technical performance and assay-related parameters (e.g., linearity
range, sensitivity to cytokine variants). The lack of information
on the relative importance of these factors and the comparative
limitations of available detection methods make it difficult to
interpret the significance of the detected variations in cytokine
levels and to compare results generated in different laboratories.
Currently available technologies for cytokine assessment include
(1) immunoassays using an ELISA principle and either absor-
bance, luminescence, or fluorochrome-tagged detection to ex-
trapolate concentrations from calibrator-based standard curves,
(2) proteomic mass spectrometry analysis of peptide composition,
and (3) functional assays, in which a test sample is assigned
arbitrary units of biological activity. Immunoassays are usually
the method of choice because they are relatively easy to perform
and standardize, and they are cytokine-specific, in contrast to
bioassays that may be influenced by cytokine redundancy and
synergistic effects.16,17
In this study, we evaluated current formats of cytokine
immunoassays, which utilize either microplate- or bead-bound
antibodies to extract the target cytokine concentration from a
complex biological background (matrix). We applied a standard-
ized approach to IL-1 and IL-6 quantification by cross-validating
immunoassays against international cytokine standards of known
biological activity. A defined medium simulating vaginal fluid
content, saline and PBS, which are commonly used for vaginal
lavage, and human blood serum, were analyzed with respect to
their effect on cytokine recovery and reproducibility both within
and between assays and laboratories. Our objectives were (1) to
identify potential sources of analytical variations of cytokine
measurement within and among independent laboratories based
on biological matrix and assay type and (2) to establish recom-
mendations for cytokine determination, data analysis, and inter-
pretation. Our results provide novel information on the role of
cytokines as biomarkers of mucosal immunity and are a step
toward their future clinical utilization for screening and monitoring
the bioactivity of safe anti-HIV-1 microbicides.
MATERIALS AND METHODS
Cytokines and Immunoassays. International Cytokine Stan-
dards and Matrix Types. Recombinant human cytokine reference
preparations have been established as international standards with
the authorization of the Expert Committee on Biological Stan-
dardization (ECBS) of the World Health Organization (WHO).18
The following panels were available through the U.K. National
Institute for Biological Standards and Control (NIBSC): recom-
binant IL-1, NIBSC code 86/680 and code 86/552, both derived
from E. coli, and human recombinant IL-6, NIBSC code 89/548,
expressed in Chinese hamster ovary (CHO) cells.19,20 Freeze-dried
preparations of the NIBSC cytokine standards were obtained by
Southern Research Institute (SRI). Each NIBSC standard was
reconstituted with distilled water (Cellgro Mediatech, Herndon,
VA) to a concentration corresponding to 100 000 IU of biological
activity/mL. The corresponding concentrations were 1 µg/mL for
IL-6 and IL-1 86/680 and 0.75 µg/mL for IL-1 86/552.19,20
Samples of these preparations were diluted 20× to a final
concentration of 5000 IU/mL in the following five matrices: saline
with pH 5-6.5 (AmTech/Phoenix Scientific, Inc., St. Joseph, MO),
Dulbecco’s PBS with Ca2+ and Mg2+, pH 7.2 (GIBCO Invitrogen,
Carlsbad, CA), human blood serum AB blood type (Valley
Biomedical, Inc., Winchester, VA), and vaginal fluid simulant
(VFS) prepared in the Channing Laboratory, Harvard Medical
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School at pH 4.5 and 7.2, as previously described.21 These
preparations were distributed to the participating laboratories for
analysis following the study design described below.
Immunoassays. The cytokine assays tested in this study
included traditional solid-phase sandwich enzyme-linked immu-
nosorbent assays (ELISA) utilizing colorimetry or luminometry
platforms, immunobead-based assays utilizing the fluidics Luminex
fluorometry platform, and a newer class of solid-phase microspot
assays based on ultra-low-noise charge-coupled device (CCD)
cameras represented by the Meso Scale Discovery (MSD)
electrochemiluminescence platform. ELISA assays were obtained
from Invitrogen BioSource (Carlsbad, CA), R&D Systems (Min-
neapolis, MN), and Pierce Endogen (Rockford, IL). Luminex assay
kits were either purchased fromMillipore Upstate (Charlottesville,
VA), or were assembled in-house using reagents from R&D
Systems. For comparison purposes in this paper, these two assays
are labeled as Beadlyte Luminex and in-house Luminex. MSD
assay kits were purchased from Meso Scale Discovery (Gaith-
ersburg, MD). A detailed description of immunoassays is provided
in Table 1.
Study Design. Aliquots of the five matrix variants of each NIBSC
cytokine standard and the five matrices (saline, PBS, serum, and
VFS at pH 4.5 or 7.2) were frozen at -70 °C and distributed to 12
participating laboratories in four countries (listed in alphabetical
order at the end of the paper). The participating laboratories were
instructed to follow a standardized protocol distributed to each
laboratory. Each laboratory performed at least three immunoas-
says, i.e., one immunoassay for each NIBSC cytokine (IL-1 86/
680, IL-1 86/552, and IL-6 89/548) (Table 1). The stock solutions
(5000 IU/mL) were diluted by the participating laboratory in assay-
specific buffer (provided by the manufacturer of each immunoas-
say) to generate three final NIBSC concentrations (spikes)
spanning the full assay range, as follows: a spike centered around
the middle of the assay calibrator range and a low and a high
spike with a log10 difference below and above the middle spike
(Table 1, column 7). Each of the three dilutions (spikes) was tested
in quadruplicate with one exception (laboratory E performed the
Quantikine assay in duplicate). The curve fit analysis was based
on averaged duplicate measurements of assay calibrators provided
with each assay kit and prepared in assay buffer as per manufac-
turer’s instructions. If multiple buffer choices were provided by
the manufacturer (as in the case of MSD and R&D Systems), the
diluents recommended for serum/plasma samples were used. A
calibrator spike (equivalent to one-fifth of top calibrator concentra-
tion for each assay) was tested in duplicate in the chemical and
biological matrices described above in each assay run and used
as an independent internal control for intra- and interassay
variation. One-half of the value corresponding to the assay
sensitivity (in pg/mL) (indicated in Table 1) was assigned to test
samples that did not produce detectable readings. The raw
readings and pg/mL values were submitted to the laboratories at
Brigham and Women’s Hospital (BWH) and SRI for data analysis.
In this report each participating laboratory is identified by a letter
from A to L that is not related to alphabetical order of names.
Data Analysis and Statistics. Reliable Detection of Fold
Difference between Cytokine Measurements. Intra-assay reproduc-
ibility was evaluated using the coefficient of variation (% CV )
100[intra-assay standard deviation/intra-assay mean]) where an
intra-assay % CV less than 20 met reliability criteria based on
precision commonly accepted for immunoassays.16 An additional
criterion for intra-assay reproducibility was based on assessing
the fold difference detectable within replicate measurements with
a power of 95% (P < 0.05) as previously described.22 For this
analysis, measured cytokine concentrations were converted to
log10 pg/mL followed by calculation of SD (standard deviation)
(21) Geshnizgani, A. M.; Onderdonk, A. B. J. Clin. Microbiol. 1992, 30, 1323–
1326.
(22) Yen-Lieberman, B.; Brambilla, D.; Jackson, B.; Bremer, J.; Coombs, R.;
Cronin, M.; Herman, S.; Katzenstein, D.; Leung, S.; Lin, H. J.; Palumbo, P.;
Rasheed, S.; Todd, J.; Vahey, M.; Reichelderfer, P. J. Clin. Microbiol. 1996,
34, 2695–2701.
Table 1. Cytokine Immunoassay Parameters
assay name kit manufacturer
sensitivity
<pg/mLa
assay range
pg/mLb
NIBSC
(IU per pg)c
number (ID) of
test laboratories
NIBSC
spikes (IU)
IL-1
BioSource ELISA Invitrogen 1 3.9-250 86/680 (0.1) 2 (A, C) 0.25, 2.5, 25
Endogen EH2 ELISA Pierce Biotechnology 1 10.24-400 86/680 (0.2) 1 (D) 0.8, 8, 80
Quantikine ELISA R&D Systems 1 3.9-250 86/552 (0.098) 4 (B, E, F, H) 0.25, 2.5, 25
QuantiGlo ELISA R&D Systems 0.4 0.5-5000 86/680 (0.1128) 2 (A, J) 5, 50, 500
Beadlyte Luminex Millipore 0.5 10-7500d 86/680 (0.244) 2 (A, K) 5, 50, 500
in-house Luminexe 4.57-3333 -(0.2)f 2 (G, I) 5, 50, 500
MSD Small Spot Meso Scale Discovery 0.1 2.44-10 000 -(0.2)f 2 (A, J) 5, 50, 500
IL-6
BioSource ELISA Invitrogen 2 19-2024d 89/548 (0.1) 2 (A, C) 2, 20, 200
Endogen EH2 ELISA Pierce Biotechnology 1 10.24-400 89/548 (0.3) 2 (D, J) 1.2, 12, 120
Quantikine ELISA R&D Systems 0.7 3.12-300 89/548 (0.131) 4 (B, E, F, L) 0.4, 4, 40
QuantiGlo ELISA R&D Systems 0.4 0.48-1500 89/548 (0.131) 2 (A, J) 1.6, 16, 160
Beadlyte Luminex Millipore 1 11-8000d 89/548 (0.128) 2 (A, K) 5, 50, 500
in-house Luminex 4.57-3333 -(0.11)f 2 (G, I) 3.5, 35, 350
MSD Small Spot Meso Scale Discovery 0.1 0.6-2500 -(0.1)f 2 (A, J) 2.5, 25, 250
a Value of the smallest dose that is not zero with 95% CI, typically calculated as the mean signal +2 SD of the zero standard read from standard
curve. b Range provided by manufacturer, if commercially available assay kit, or by testing laboratory, if in-house assay. c WHO-recommended
standard, provided by the U.K. National Institute of Biological Standards and Control (NIBSC), was used by manufacturer to calibrate the assay.
d May vary by lot as per manufacturer instructions; however, it did not vary in this study. e Assay was designed in-house using separate commercially
available reagents. f Manufacturer calibrated against recombinant human IL-1 or IL-6 standards from R&D Systems, which have been calibrated
by R&D Systems against NIBSC IU.
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from replicate measures. The fold difference in cytokine concen-
tration, for which the assay would have 95% power to detect, was
calculated based on the intra-assay SD (R ) 0.05, two-tailed
unpaired t test, degrees of freedom ) 4, StatMate, version 2, 2006;
GraphPad software). According to this analysis, an intra-assay log10
SD < 0.12 allows the power to detect at least 1.5-fold difference
between measured values, for all assays evaluated. Interassay
differences were graphically compared using linear regressions
fitted to the nominal and measured data provided by laboratory
A, which performed a test with each of the four assay platforms
assessed in this studyscolorimetric and luminometric ELISA,
electrochemiluminescence-based MSD, and fluorescence-based
Luminex. Interlaboratory differences were assessed both graphi-
cally, using linear regressions fitted to the nominal and measured
data provided by four laboratories running the same assay
(Quantikine ELISA) with each NIBSC cytokine, and by testing
for interlaboratory reproducibility where a nonsignificant effect
of laboratory was used as an indicator of reproducibility (R ) 0.01,
Kruskal-Wallis, PROC NPAR1WAY, SAS, version 9.1.3). The
pooled data from all laboratories running the same assay were
used to determine the smallest detectable interlaboratory fold
difference and to test for the affects of assay factors on cytokine
recovery.
Assay Linearity and Accuracy. Assay linearity was measured by
linear regression, where the coefficient, r2, was derived from the
relationship between nominal values (WHO IU/mL) of the low,
middle, and high spike levels of each NIBSC standard and their
measured concentrations (pg/mL) in each immunoassay andmatrix.
An r2 ) 1 indicates a straight linear relationship. The accuracy of
each assay, e.g., its ability to recover the gravimetric concentration
of each cytokine, was tested by comparison of measured to nominal
weight/volume (w/v) concentrations of NIBSC cytokines. Because
the linearity ranges of most immunoassays do not overlap (Table
1), a nominal value of 25 IU/mL NIBSC standard that represents
a common overlap point of all assays regardless of assay platform
or cytokine was chosen for interassay comparisons. An assay-
specific measured pg/mL value for the 25 IU/mL nominal spike
was determined for each matrix-cytokine variant by interpolation
from the linear regression lines generated from each assay (PROC
REG, SAS, version 9.1.3). The conversion from IU/mL to w/v
concentrations was performed using ratios provided by NIBSC,
which were 1 pg ) 0.1 IU for IL-1 86/680 and IL-6 89/548, and
1 pg ) 0.10933 IU for IL-1 86/552. Thus the expected w/v values
corresponding to a 25 IU/mL spike were 250 pg/mL for IL-1
86/680 and IL-6 89/548 and 228.67 pg/mL for IL-1 86/552,
respectively. The null hypothesis that assay-measured values were
not different from these nominal concentrations was tested, i.e.,
t ) (b1 - b2)/SE(b1, b2) at P < 0.01 (two-tailed t test), where b1 and
b2 were, respectively, the estimated and nominal spiked concentra-
tions to be compared, and SE was the pooled standard error of
the slope calculated using linear regression (PROC REG, SAS,
version 9.1.3).
Factors with Significant Impact on Analytic Cytokine Recovery.
The assay-specific measured values were further used to calculate
% recovery from each matrix in each assay as 100(measured pg/
mL)/(nominal pg/mL). This approach allowed comparisons
between middle spike level NIBSC cytokines and assay calibrators
regardless of differences in nominal values. Recovery greater than
100% indicates that the measured values for a matrix were higher
than the nominal value of the spike, and a recovery less that 100%
indicated that the measured values for a matrix were lower than
the nominal value of the spike. The effect of biological matrices
on % recovery from the middle NIBSC spike and the calibrator
spike were tested using Kruskal-Wallis analysis of variance and
Dunn’s multiple comparisons test (PROC NPAR1WAY, SAS,
version 9.1.3).
To examine the impact of experimental variables on assay
measurement, a multiple regression analysis was performed where
the dependent variable was % recovery, and the independent
variables were number of replicates, pH of the vaginal fluid
simulant, biological complexity of the matrix, and assay type. The
hypothesis tested by a multivariate regression is that there is a
joint linear effect of the set of independent variables on the
dependent variable. Hence, the null hypothesis is that slope of all
coefficients is simultaneously zero. A significant t value indicates
that the slope for that independent variable (i.e., an assay variable)
makes an independent contribution to account for variance in the
dependent variable (i.e., % recovery). The data used in this analysis
were the % recovery of the low, middle, and high NIBSC cytokines
and the % recovery of the one-fifth top calibrator. A stepwise
multiple regression model (PROC REG, SAS, version 9.1.3) was
undertaken using a stringent P value for entry (P< 0.05). Contrast
variables were created to include the categorical variables of assay,
matrix pH, and complexity in the multiple regression model for
each cytokine. For all other statistical tests an R of 0.01 was used,
as the aim of this study was to identify robust effects in model
systems that could be predicted to play a role in the measurement
of cytokines for clinical trials that involve heterogenic populations
and multiple laboratories.
RESULTS
Assay Performance and Reliable Detection of Fold Dif-
ference in Cytokine Levels. Assay performance was assessed
by intra-assay variation (% CV), fold difference reliably detectable
with P ) 0.05 (based on log10 SD), assay linearity (slope and r2
values derived from the linear regression for the low, medium,
and high spiked samples), and detection accuracy (recovery of
nominal gravimetric concentrations).
As shown in Table 2, most measurements (75.56-100%) across
laboratories and assays met the <20% CV criterion for intra-assay
reproducibility. The range in r2 values (0.79-1) indicated a strong
linear relationship between measured and nominal concentrations
for the spiked samples. The median intra-assay log10 SDs were
below 0.12, and the fold difference in cytokine concentration that
would be detected with 95% power (P ) 0.05) was between 1.45
and 1.65 (Table 2). Thus, the intra-assay measurements met the
set criterion for sensitive reliable comparison of cytokine levels.
The reliability of cytokine comparisons was reduced when the
data were pooled frommultiple laboratories (log10 SD) 0.04-0.65,
detectable fold difference ) 1.63-16.37, Table 2) or from multiple
biological matrices (log10 SD ) 0.07-0.78, detectable fold differ-
ence ) 1.84-26.07, Table 2). The in-house Luminex assay met
intra-assay but not interlaboratory reliability criteria. Thus, if data
were pooled from multiple laboratories using the in-house Lu-
minex assay, a difference much higher than 2-fold (>6.31-16.37-
fold) would be required to achieve 95% power of statistical
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significance (Table 2). It was predicted that the commercial assays
would be able to detect 1.68-8.48-fold differences in cytokine
concentration if measurements were made by multiple laborato-
ries, with (electro)chemiluminescence-based assays (MSD and
QuantiGlo) being consistently most discriminative, detecting <2-
fold differences (Table 2).
Assay accuracy varied considerably depending on assay and
cytokine tested (Figure 1). The pg/mL concentrations returned
by the linear regression model for a 25 IU/mL equivalent of
NIBSC spike were either higher or lower than the nominal w/v
spike value (P < 0.01, t test) in most IL-1 runs [92% of 86/552
(Figure 1A) and 86% of 86/680 assay runs (Figure 1B)] and in all
IL-6 runs (Figure 1C). The Quantikine, QuantiGlo, and MSD
immunoassay extracted IL-1 86/552 levels above the nominal
values across all matrices (P < 0.01, Figure 1A). In contrast, the
BioSource and Luminex Upstate Beadlyte assays were found to
underestimate nominal IL-1 86/552 levels across all matrices
(Figure 1A). Neither of the two laboratory results for in-house
Luminex IL-1 86/552 measurements were close to the expected
cytokine level; laboratory G results were extremely low and
laboratory I results were extremely high (Figure 1A). Endogen-
measured values for IL-1 86/552 were higher in PBS pH 7.2 but
lower in all other matrices as compared to nominal values (Figure
1A). All IL-1 86/680 measurements were lower than nominal
values with the notable exceptions of in-house Luminex (laboratory
I) and Beadlyte Luminex (laboratory A) assays (Figure 1B). Most
measured levels of IL-6 89/548 were below the expected nominal
concentration (P < 0.01, t test, Figure 1C).
Interlaboratory and Interassay Reproducibility. There was
a general consistency in the results obtained from four laboratories
using the same Quantikine assays with greatest interlaboratory
differences found in the lower end of the assay detection range
(Figure 2A). A nonsignificant (P > 0.01, Kruskal-Wallis) effect
of laboratory on cytokine recovery was used as an indicator of
interlaboratory reproducibility when at least two laboratories ran
the same assay (Table 3). Reproducible interlaboratory measure-
ment of all cytokines was found only for the MSD assays (Table
3). In the case of the Quantikine assays, although the linear
regression model showed interlaboratory consistency (Figure 2A),
the high intra-assay reproducibility in each laboratory (% CV <
20 and log10 SD < 0.12, Table 2) contributed to a statistically
significant interlaboratory difference (P < 0.01, Kruskal-Wallis).
Each assay type was assessed for significant intercytokine
differences in spike recovery (Kruskal-Wallis, Mann-Whitney,
and Dunn’s test, P < 0.01). The different performance of each
assay by cytokine preparation (midrange spikes of NIBSC and
assay calibrator) is illustrated in Figure 3, and probability values
for all interlaboratory and intercytokine differences in % recovery
measurements are summarized in Table 3. As expected, the
median (interquartile range) % recovery for all assay calibrators
was optimal for both IL-1 [108.00 (53.44)%, Figure 3C] and IL-6
[95.02 (26.53)%, Figure 4B]. However, the recovery of the NIBSC
spikes differed (Mann-Whitney P < 0.001). The recovery of IL-
1 86/680 was lower [93.76 (53.22)%, Figure 3B] than the IL-1
86/552 recovery [125.25 (90.11)%, Figure 3A]. The recovery of
IL-6 89/548 was below the nominal concentrations in all IL-6 assays
tested [41.70 (48.78)%, Figure 4A].
Interassay reproducibility was assessed when one laboratory
tested multiple assays representing the four major cytokine
detection platforms, e.g., absorbance ELISA (BioSource), chemi-
luminescence ELISA (QuantiGlo), fluorimetric immunobead assay
(Beadlyte Luminex), and electrochemiluminescence assay (MSD).
For all IL-6 89/548 and for IL-1 86/680 measurements (Figure
2B) interassay disparities were greater in the low-concentration
range of the assays coinciding with the lowest standard spikes
(0.25-5 IU/mL). For IL-1 86/552 measurements (Figure 2B, left
panel) interassay disparities were seen over the entire cytokine
detection range.
Impact of Matrix on Interlaboratory Variation of Cytokine
Measurements. The effect of matrix on assay measurements was
tested using the % recovery of the middle NIBSC spikes (Figure
3, parts A and B, and Figure 4A) and the assay calibrator spikes
(Figure 3C and Figure 4B). Percent recovery was calculated in
each assay, and results were pooled when multiple laboratories
Table 2. Assay Linearity and Precision for the WHO Spiked Samples across All Participating Laboratoriesa
log10 SD detectable fold differenceb
cytokine/assay intra-assay interlaboratory intermatrix intra-assay interlaboratory intermatrix CV < 20% (%)c linearity r2
IL-1
BioSource 0.04 (0.05) 0.07 (0.19) 0.15 (0.20) 1.65 1.84 2.46 75.56 0.99 (0)
Endogen 0.03 (0.03) NAd 0.07 (0.08) 1.61 NA 1.84 96.67 0.98 (0.02)
Quantikine 0.01 (0.04) 0.13 (0.27) 0.14 (0.26) 1.5 2.35 2.39 86.67 1.00 (0.00)
QuantiGlo 0.01 (0.02) 0.08 (1.24) 0.08 (1.17) 1.45 1.9 1.89 98.33 1.00 (0.01)
Beadlyte Luminex 0.02 (0.02) 0.07 (0.29) 0.37 (0.28) 1.54 1.84 5.76 90 0.99 (0.01)
in-house Luminex 0.03 (0.03) 0.65 (0.08) 0.62 (0.07) 1.59 16.37 14.68 90 0.98 (0.03)
MSD Small Spot 0.03 (0.03) 0.05 (0.04) 0.07 (0.05) 1.56 1.68 1.88 96.67 0.99 (0.02)
IL-6
BioSource 0.04 (0.05) 0.30 (0.31) 0.51 (0.18) 1.64 4.4 9.49 76.67 0.99 (0.01)
Endogen 0.03 (0.05) 0.48 (0.58) 0.66 (0.43) 1.59 8.48 16.82 76.67 0.98 (0.04)
Quantikine 0.02 (0.02) 0.07 (0.05) 0.21 (0.01) 1.54 1.86 3.12 91.67 1.00 (0.00)
QuantiGlo 0.03 (0.03) 0.08 (0.1) 0.28 (0.04) 1.56 1.89 4.06 93.33 0.99 (0.01)
Beadlyte Luminex 0.02 (0.03) 0.41 (0.53) 0.78 (0.33) 1.54 6.5 26.07 96.67 0.79 (0.51)
in-house Luminex 0.02 (0.03) 0.40 (0.16) 0.48 (0.18) 1.54 6.31 8.62 90 1.00 (0.01)
MSD Small Spot 0.03 (0.02) 0.04 (0.01) 0.21 (0.06) 1.56 1.63 3.1 100 0.99 (0.01)
a Comparisons within (i) replicate samples (intra-assay), (ii) samples pooled from multiple laboratories (interlab), and (iii) samples pooled for
the five different biological matrices (intermatrix). SD (log10 pg/mL) and linearity coefficient r2 are expressed as median (interquartile range).
b The fold difference in cytokine concentration for which the assay would have 95% power to detect with P < 0.05. c The proportion (%) of
measurements with an intra-assay CV <20%. d NA: not applicable (only one laboratory ran this assay).
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used the same assay kit. As can be seen from Table 2, when
pooling results from multiple laboratories a 1.6- to 8.5-fold
difference would be required for any effect to be determined
significant with the exception of the in-house Luminex assay
where reliable interlaboratory detection required more than 16-
fold difference. Therefore, only matrix effects consistent across
laboratories could be shown by this type of analysis.
Matrix effects on IL-1 recovery varied depending on cytokine
variant and immunoassay variant. No effects of matrix on recovery
of both IL-1 86/552 and 86/680 were found by Biosource, Quan-
tikine, MSD, or in-house Luminex assays. The Beadlyte Luminex
IL-1 assay was most sensitive to matrix, showing lowest recovery
in PBS (Figure 3, parts A and B, P < 0.01, Dunn’s test). The
QuantiGlo assay showed matrix effects only on the recovery of 86/
680 being lowest in saline (Figure 3B, P < 0.01, Dunn’s test). The
Endogen assay also showed matrix-sensitive recovery of NIBSC
cytokines, but the significance of these findings could not be
confirmed with pooled data since only one laboratory ran this assay.
The recovery of IL-1 calibrator spikes was significantly affected by
matrix only in the in-house Luminex assay, being lowest in serum
and comparable between PBS, saline, and VFS, and in the Quantikine
assay, being lower in PBS than in VFS at pH 7.2 (P < 0.01, Dunn’s
Test, Figure 3C). Unlike IL-1, NIBSC IL-6 recovery was consistently
affected by matrix type in most (six of seven) assays tested, with
markedly lower recovery in PBS and saline as compared to VFS and
serum (Figure 4A, P < 0.01, Dunn’s test). In contrast, matrix had
no significant effect on recovery of IL-6 assay calibrator spikes
regardless of assay platform (Figure 4B).
Figure 1. Assay accuracy for predicted measurements of 25 IU spikes of IL-1 86/552 (A), IL-1 86/680 (B), and IL-6 89/548 (C) across
laboratories and kits. Values were derived from a linear regression curve with the standard error of the mean slope represented by error bars.
The horizontal dashed line indicates nominal weight/volume concentrations of 25 IU/mL, which is 228.67 pg/mL for IL-1 86/552 and 250 pg/mL
for IL-1 86/680 and IL-6 89/548.
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Relative Importance of Biological and Technical Variables.
A multiple regression model was used to evaluate the relative
importance of major parameters tested in this study such as
pH of the vaginal fluid simulant, the relative complexity of the
biological matrix, the assay type, and technical performance
parameters reflecting interassay and inter-replicate (intra-assay)
reproducibility of cytokine recovery. Multiple regression analy-
sis was used to determine which, if any, of these factors tested
could explain the variation found in cytokine recovery. The final
multiple regression models were found to significantly explain
recovery of the cytokines tested (r2 ) 0.10-0.45, P < 0.001,
Table 4). The nonsignificant effect of replicate indicated the
consistency of intra-assay results and is further evidence of
assay reliability across all cytokine measurements reported in
this study (Table 4). The variation in recovery of IL-1 86/552
and IL-6 89/548 cytokines was influenced by the assay type
for all cytokines tested (Table 4) with the considerable
interassay differences illustrated in Figure 3A-C. Variation in
recovery of IL-1 86/680, IL-1 kit calibrator, and IL-6 89/548
was explained by the complexity of the biological matrices
[(PBS and saline) < VFS < serum, Table 4]. There was no
effect of pH in the multiple regression models for any of the
cytokines tested when VFS at pH 7.2 was compared to VFS
buffered at pH 4.5 in the context of the vaginal fluid matrix
(Table 4).
DISCUSSION
This is the first study to assess the relative importance of
technical and biological variables affecting multicenter mea-
surement of proinflammatory cytokines in the context of the
vaginal mucosal fluid matrix. The study compared complex
biological fluids (e.g., human serum or surrogate vaginal fluid)
versus simple protein-free matrix (e.g., buffered or nonbuffered
saline both widely used to sample vaginal cytokines by lavage).
Figure 2. Interlaboratory (A) and interassay (B) comparison of results obtained for IL-1 86/552, IL-1 86/680, and IL-6 89/548 cytokines from
four laboratories using the same Quantikine ELISA (A) and from laboratory A using four assay types (B). Each line represents linear regression
analysis between nominal values (WHO IU/mL) of the low, middle, and high spike of each NIBSC standard and their measured concentrations
(pg/mL) in one assay run.
Table 3. Probability of Interlaboratory and Intercytokine Differences in Recovery of Cytokines across Assays
interlaboratory
IL-1 IL-6 intercytokine
assay 86/552 86/680 assay calibrators 89/548 assay calibrators IL-1 IL-6
BioSource <0.0001a NA <0.0001 0.280 0.007 <0.0001 0.005
Endogen NAb NA NA <0.0001 0.023 <0.0001 <0.0001
Quantikine <0.0001 <0.0001 0.018 0.054 <0.0001 <0.0001 <0.0001
QuantiGlo <0.0001 0.003 <0.0001 0.465 0.002 <0.0001 <0.0001
Beadlyte Luminex 0.552 0.001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
in-house Luminex <0.0001 <0.0001 0.014 <0.0001 0.199 0.054 <0.0001
MSD Small Spot 0.094 0.049 0.028 0.814 0.049 <0.0001 <0.0001
a P < 0.01 indicates that the % recovery was different between laboratories or between cytokines (Mann-Whitney, Kruskal-Wallis). b NA ) not
applicable; the analysis was not applicable when <2 laboratories provided data from the same kit.
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It was determined that matrix complexity unequally affected
cytokine measurement, depending on individual cytokine
preparation as well as detection platform or assay. In the case
of IL-1, the matrix effect varied by detection platform. In
contrast, matrix complexity affected IL-6 measurements regard-
less of assay or detection platform, with saline and PBS
consistently returning lower IL-6 values. In general, the analytic
recovery of spiked cytokine assay calibrators was less sensitive
to matrix variation than that of recombinant biologically active
NIBSC cytokine standards, which should more closely mimic
native endogenous cytokines. These results suggest that
biologically active or endogenous cytokines rather than assay
calibrators should be spiked into relevant biological fluids to
estimate possible effects of fluid matrix on cytokine measure-
ments and to establish a standard procedure for future
interlaboratory measurement of cytokines as biomarkers in
clinical trials. Our results also suggest that the media used for
vaginal washing or dilution of samples may play a critical role
in the recovery of cytokine concentrations, and therefore,
uniform vaginal sampling should be applied across clinical
trials. The possibility for underestimating concentrations of
some cytokines should be considered, and errors should be
estimated by assessing each cytokine recovery in the medium
of choice.
Differences in measured cytokines across assay platforms
could not be explained solely by different nominal values of assay
Figure 3. Effect of matrix on percent recovery of the middle spike of IL-1 NIBSC cytokines (A and B) and assay-specific calibrators (C). Box
plots represent medians and interquartile range of each assay. The horizontal solid line represents the median from all assays. The P values
indicate probability of matrix effects for each assay type where n.s. is a nonsignificant (P > 0.01) effect of matrices (Kruskal-Wallis ANOVA,
Dunn’s Post Hoc tests).
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calibrators provided by each manufacturer. Similarly to our study,
previous studies of human blood have reported significant inter-
assay variations.23,24 In those studies, various assays generated
similar patterns of IL-6 blood plasma levels; however, absolute
concentrations differed between ELISA kits produced by different
manufacturers.23 Neither in those nor in our study did conversion
of cytokine concentrations from pg/mL to NIBSC IU/mL eliminate
interassay differences. Our study confirms the need for use of
internal calibrator controls along with matrix-specific conversions
to allow interassay and interlaboratory meta-analysis.
Antibody-based detection of cytokines in complex biological
fluids can be complicated by denaturation of epitopes by fluid
components as well as by the physiological variance of cytokine
polymerization, glycosylation, soluble receptor binding, or deg-
radation that may not be equally recognized by the detection
antibodies used in different assays. Recombinant proteins used
for calibration and generation of antibodies for various immu-
noassays may have various degrees of glycosylation and other
posttranscriptional modifications depending on bacterial, yeast,
or mammalian rDNA expression systems19 which may explain
(23) Khan, S. S.; Smith, M. S.; Reda, R.; Suffredini, A. F., Jr. Cytometry, Part B
2004, 61B, 35–39.
(24) Aziz, N.; Nishanian, P.; Mitsuyasu, R.; Detels, R.; Fahey, J. L. Clin. Diagn.
Lab. Immunol. 1999, 6, 89–95.
Figure 4. Effect of matrix on percent recovery of the middle spike of the IL-6 NIBSC cytokine (A) and assay-specific calibrators (B). Box plots
represent medians and interquartile range of each assay. The horizontal solid line represents the median from all assays. The P values indicate
probability of matrix effects for each assay type where n.s. is a nonsignificant (P > 0.01) effect of matrices (Kruskal-Wallis ANOVA, Dunn’s
Post Hoc tests).
Table 4. Multiple Regression Analysis of Relative Effects of Assay Factors on Cytokine Recovery
prob(t)a
variables IL-1  86/552 IL-1 86/680 IL-1 (kit) IL-6 89/548 IL-6 (kit)
Biological Matrix
matrix pHb 0.756 0.432 0.796 0.836 0.103
matrix complexityc 0.127 <0.0001d <0.0001d <0.0001d 0.0675
Technical Parameters
assay platform <0.0001d <0.0001d <0.0001d <0.0001d <0.0001d
replicate 0.13 0.995 0.695 0.829 0.309
final model adjusted r2 0.1 0.41 0.45 0.13 0.23
prob(F)e <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
a Probability of the t test for the null hypothesis that the regression coefficient of each variable ) 0. b For the vaginal fluid simulant only where
pH 4.5 was compared to pH 7.2. c Where matrix complexity was determined to increase from PBS and saline < vaginal fluid simulant < serum.
d Variables included in final model, where prob(t) < 0.05. e Probability of the F test of the significance of R, where a prob(F) < 0.05 indicates that
the model is significantly better than would be expected by chance.
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some differences found between assay calibrators and NIBSC
standards. For example, IL-1 is initially translated as a biologically
inactive precursor molecule that is subsequently processed into
a mature protein associated with IL-1 bioactivity.25 Both may be
available in biological fluids. In the case of vaginal fluid, the
presence of mucus can introduce another layer of variability since
it can bind some cytokines and thus affect their recognition by
capturing antibodies or may nonspecifically attach to immuno-
beads or assay plates thus affecting downstream assay events.
In this study, the two biologically active international reference
preparations of IL-1 differed in terms of sensitivity to matrix
complexity. IL-1 calibrators were also sensitive to matrix com-
plexity but only in two out of seven assays. In contrast, the
recovery of the NIBSC, but not the calibrator IL-6 variants, differed
significantly in terms of their sensitivity to matrix types, regardless
of assay type. Although the recovery of NIBSC IL-6 was lower in
PBS and saline as compared to serum and the defined vaginal
simulant, assay calibrators were equally recoverable from all
matrices across all assays. In analogy to results obtained with
natural IL-6 present in blood, different assays provided different
recovery of IL-6 89/548 in the vaginal fluid simulant. This could
be dependent upon the fact that recombinant IL-6 89/548 is
glycosylated similarly to the natural cytokine19 and its detection
would depend on the level of recognition of protein or carbohy-
drate epitopes by the antibody pairs of each assay.
The interlaboratory differences observed in this study were
not due to sample handling or technical skills since variation of
sample handling was minimized by following a standardized
operational procedure developed for each assay listed in Table 1
and since good intralaboratory and intra-assay reproducibility was
achieved within each matrix type and within each assay platform.
The small intra-assay variation was confirmed using multiple
indexes (i.e., % CV, log10 SD, and estimation of detectable fold
differences).
The interlaboratory variation was most significantly associated
with assay type and platform as demonstrated by the bar sizes in
Figures 3 and 4 and by the fold differences reliably detectable in
each assay (Table 2). Thus, the sources of interlaboratory variation
appear inherent in cytokine-platform or matrix-platform interac-
tions. The complex matrices (serum and vaginal fluid simulant)
were consistently associated with higher interlaboratory variation
in all assays except the QuantiGlo and MSD (Figures 2 and 3),
which detect a luminescent signal at 620 nm thus eliminating the
problem with color quenching by matrix components that may
occur in regular absorbance ELISA or fluorimetric Luminex
assays. In addition, MSD uses labels that emit light when
electrochemically stimulated where the stimulation event (electric-
ity) is decoupled from the signal (light) thus minimizing back-
ground. Nonuniform matrix interactions with immunobeads in the
Luminex platform may add an additional layer of variation, which
is complicated by the fluidics nature and dependence on efficient
washing of the beads between immunoassay steps. Interlaboratory
variability has been found previously for noncommercial assays
for quantification of HIV-1 RNA in seminal plasma where com-
mercial assays were found to demonstrate highly reproducible
(intra-assay log10 SD 0.11-0.32) and noncommercial (in-house)
assays less reproducible results (intra-assay log10 SD 0.12-0.75).26
A multicenter study suggested that the lack of reproducibility
found for noncommercial assay measurements could be due to
the fact that reagents for commercial kits are produced in “large
and well-characterized” lots.26 Thus, variation of immunobead and
antibody lots obtained from different manufacturers that have not
been as rigorously subjected to quality control and cross-
calibration as commercially assembled kits may be an additional
explanation for high interlaboratory variation in in-house as-
sembled Luminex assays.
In our study the commercial assay kits as well as the assays
compiled in-house from different commercially available reagents
showed high inter-replicate reproducibility allowing reliable detec-
tion of 1.5-fold intra-assay difference in concentration levels
regardless of cytokine type. However, interlaboratory variation
significantly decreased the level of confidence in detectable
difference. Our data indicate that IL-6 levels, for example, would
have to vary by at least 6-fold in order for multiple laboratories
using the Luminex platform to detect reliable differences, provided
a uniform biological fluid (matrix) was used. With matrix variation,
the threshold for reliable detection of IL-6 differences increased
to >26-fold in Luminex Beadlyte and >8-fold in several other
assays. Matrix variation affected less the statistical power to detect
differences in IL-1 levels. These data emphasize the importance
of uniform biological sampling techniques and careful analysis of
matrix interferences. Because of high interlaboratory reproduc-
ibility regardless of specific cytokine tested, the chemilumines-
cence-based assays (QuantiGlo and MSD) appear more suitable
for multicenter study comparisons. Our study suggests that if
uniform platform use is not feasible for financial or technical
reasons, each multicenter study should appoint a reference
laboratory to perform interassay comparisons to determine the
confidence of fold-difference detection in each specific biological
fluid and for each cytokine assessed.
In summary, the cytokine measurement methods evaluated
here were found to be reproducible for laboratories using
commercial assay platforms; however, the measured values of
identical samples varied across laboratories and assay platforms.
Our data indicate that variability introduced by the sampling fluid
and assay type or detection platform may confound interlaboratory
or interstudy comparisons. The discrepancy between matrix
recovery of assay calibrators and biologically active cytokine
variants, which was especially obvious for IL-6 assays, may lead
to a significant under- or overestimation of cytokine concentrations
in complex biological fluids such as vaginal fluids and blood. It is
important to understand that these effects may occur in every day
analytical practice not limited to the case of cytokine immunoas-
says. To avoid their impact, any laboratory should prepare their
own normality ranges in the relevant types of clinical samples.
Our study emphasizes the need for assay choices based on criteria
for reliable interlaboratory comparisons, which goes beyond the
scope of vaginal cytokine measurement and microbicide research.
Along with parameters commonly provided by manufacturers
(e.g., assay sensitivity, lower limit of detection, and assay precision
determined by reproducibility of replicate measurements), im-
munoassay utility should be evaluated also by matrix-specific fold
(25) Arend, W. P. Cytokine Growth Factor Rev. 2002, 13, 323–340.
(26) Fiscus, S. A.; Brambilla, D.; Coombs, R. W.; Yen-Lieberman, B.; Bremer,
J.; Kovacs, A.; Rasheed, S.; Vahey, M.; Schutzbank, T.; Reichelderfer, P. S.
J. Clin. Microbiol. 2000, 38, 2348–2353.
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change in cytokine concentration reliably detectable by multiple
comparisons methods. Of all the assays evaluated in this study,
the (electro)chemiluminescent platform appeared to be the most
reliable platform for detection of a e1.5-fold change in IL-6 and
IL-1 concentrations. However, future validation studies are
needed to determine the biological significance of the magnitude
of change for each biomarker candidate. It is recommended that
prior to adoption of a standardized methodology, cytokine
measurements from clinical trials be reported not only in terms
of absolute ranges but also in terms of fold differences between
samples with defined clinical characteristics.
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